Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Inova Health Care Services
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07023666CT.gov Early Screening and Treatment of Heart Complication in Sickle Cell Disease | — | Recruiting | — | — | — |
NCT05392101CT.gov Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease | — | Completed | — | — | — |
NCT01511848CT.gov Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload | — | Unknown | — | — | — |
NCT00981370CT.gov Clinical Importance of Treating Iron Overload in Sickle Cell Disease | — | Terminated | — | — | — |
NCT00749515CT.gov Pilot Study for Patients With Poor Response to Deferasirox | — | Completed | — | — | — |
NCT00235391CT.gov Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload | — | Completed | — | — | — |
NCT00110617CT.gov Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients | — | Completed | — | — | — |
NCT01090323CT.gov Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO). | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sickle Cell Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Deferasirox (this asset) | Inova Health Care Services | Approved | BB · 67 |
| Glutamine | Ain Shams University | P4 | BBB |
| Hydroxyurea | St. Jude Children's Research Hospital | P4 | BB |
| Crizanlizumab | Novartis Pharmaceuticals | P4 | BB |
| Magnesium Metallicum | Medical College of Wisconsin | P3 | BB |
| Nivestim | St. Jude Children's Research Hospital | P4 | BB |
| ARG | Tanta University | P3 | BB |
| Fentanyl | University College Dublin | P4 | BB |
| Nepenthe | Oman Medical Speciality Board | P4 | BB |
+42 more in the Sickle Cell Disease cohort
Other indications for Deferasirox
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Iron Poisoning | — | P4 | A · 82 |
| Hemosiderosis | — | P4 | A · 81 |
| Beta-Thalassemia Major | — | P4 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Deferasirox in Sickle Cell Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/deferasirox-sickle-cell-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →